A5036136269- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hospital Admissions and Outcomes
- Healthcare Policy and Management
- Transgenic Plants and Applications
- Soft tissue tumor case studies
- Pharmaceutical studies and practices
- Primary Care and Health Outcomes
- Acute Lymphoblastic Leukemia research
- Atrial Fibrillation Management and Outcomes
Johns Hopkins All Children's Hospital
2020-2025
Johns Hopkins University
2020-2025
St. Francis College
2023
Whalen Biomedical
2023
Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As bacteria-derived enzyme, asparaginase highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction pegaspargase, PEGylated version Escherichia coli-derived asparaginase. Erwinia chrysanthemi (recombinant)-rywn (recombinant Erwinia) an alternative those pegaspargase. Here, we describe 11-year-old boy relapsed ALL who...
10008 Background: NTRK1/2/3 gene fusions (TRK fusions) occur in a range of pediatric cancers and are the canonical molecular alterations IFS. Larotrectinib is highly selective TRK inhibitor that FDA-approved for fusion solid tumors patients with no satisfactory alternative treatments or whose cancer has progressed following initial treatment. ADVL1823 (NCT03834961) evaluated larotrectinib children newly diagnosed positive two histology-based cohorts. Cohort A enrolled IFS focus this...
PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as frontline therapy with defined duration of treatment. ADVL1823 evaluated in patients newly diagnosed response-adapted local control. METHODS Patients received twice daily 28-day cycles predefined treatment, ranging from 6 to 26 depending on response surgical...
TPS10560 Background: In children, fusions of the NTRK1/2/3 genes (TRK fusions) occur in soft tissue sarcomas, including infantile fibrosarcoma (IFS), congenital mesoblastic nephroma, high- and low-grade gliomas, secretory breast carcinoma, papillary thyroid cancer. Rarely, TRK also Ph-like acute lymphoblastic leukemia myeloid leukemia. Larotrectinib is a selective inhibitor FDA-approved for treatment fusion solid tumors patients with no satisfactory alternative treatments or whose cancer has...